Log In
BCIQ
Print this Print this
 

METSporine (NM0133)

  Manage Alerts
Collapse Summary General Information
Company Nanomerics Ltd.
DescriptionImmunosuppresant for the treatment of corneal graft rejection and eye disorders
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPhase I
Standard Indication Ophthalmic (unspecified)
Indication DetailsTopical ocular delivery of hydrophobic drugs
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today